Infosys, ICICI Bank, Tata Motors: Stocks to buy in 2017

With key events such as developments in the European Union (Brexit), policy initiatives by Donald Trump after he assumes office as the US President, monetary policy framework of global central banks, outcome of Assembly elections back home and the demonetisation impact on corporate earnings, progress on implementation of the goods and services tax (GST) bill, calendar year 2017 promises to be an eventful year for equity investors.

 
Going forward into 2017, analysts expect the Indian economy to recover from the demonetisation shock from Q2CY17 onwards, as the liquidity crunch wanes away and the pent up demand comes back to the fore. In this backdrop, they expect Indian equities to perform well.

 
“India’s economy is in transition: towards greater formalisation, lesser corruption, better infrastructure and improved governance. Some of these transitional reforms – the recent demonetisation and implementation of the goods and services tax (GST) – along with a reversal of the terms-of-trade gains will hurt growth in the near term but are laying the ground for a faster growth rebound in 2018,” said Sonal Varma, executive director and India Economist at Nomura in a recent report.





 
“We expect growth to be largely unchanged at 7.1% in 2017, but to rise sharply to 7.7% in 2018,” she adds.

 
With myriad investing options available with investors, here is a quick compilation of top stock recommendations for calendar year 2017 from brokerages.

 
DEUTSCHE EQUITIES

 
Aurobindo Pharma, Bank of Baroda (BoB), BPCL, Godrej Consumer, Hindalco, HPCL, Nestle, NTPC, Petronet LNG, Reliance Industries (RIL), State Bank of India (SBI), Sun Pharma, Tech Mahindra


MOTILAL OSWAL RESEARCH

 
Tata Motors: Target Price - Rs 610

 
ICICI Bank: Target Price - Rs 337

 
Canfin Homes: Target Price - Rs 2,260

 
Sterling Tools: Target Price - 1,207

 
APL Apollo Tubes: Target Price - Rs 1,248

 
RELIGARE

 
Fiem Industries: Target Price - Rs 1,315

 
Castrol India: Target Price - Rs 483

 
Wonderla Holidays: Target Price - Rs 430

 
Jain Irrigation Systems: Target Price - Rs 104

 
ANGEL BROKING

 
Asian Granito: Target Price - Rs 351

 
Infosys: Target Price - Rs 1,249

 
Jagran Prakashan: Target Price - Rs 225

 
Power Grid Corporation: Target Price - Rs 223

 
Alkem Laboratories: Target Price - Rs 1,989

 

Comments

Post a Comment

Popular posts from this blog

JCB India launches its new 3DX ecoXPERT

Image
JCB India launches its new 3DX ecoXPERT Designed to give significant savings in Fuel and Maintenance Integrated with “IntelliPerformance” India’s leading manufacturer of Earthmoving and Construction Equipment, JCB India launched its all new 3DX ecoXPERT Backhoe Loader in Bhopal.With JCB’s ‘IntelliPerformance’ technology, which efficiently manages the energy demands of the machine, the intelligent new 3DX ecoXPERT saves fuel and reduces maintenance costs, thus leading to significant savings.Mr. Subir Kumar Chowdhury, Managing Director & CEO of JCB India says, “We are delighted to have launched our new Backhoe Loader, the 3DX ecoXPERT. This new machine is designed to give up to 12% savings on fuel and up to 22% savings on maintenance. Equipped with ‘IntelliPerformance’ technology the machine comes with advanced telematics called JCB Livelink which enables real-time fleet management of equipment for our customers. JCB has pioneered in integrating Smart technologies such as Internet o
Read more

Dr. Reddy’s Laboratories announces the first generic launch , Delayed Release Tablets in the U.S. Market

Image
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, a therapeutic equivalent generic version of Vimovo ® (Naproxen and Esomeprazole Magnesium) Delayed-Release Tablets approved by the U.S. Food and Drug Administration (USFDA).“This launch is a testament to our core strengths in areas of research and development and intellectual property,” says Marc Kikuchi, Chief Executive Officer, North America Generics. “We are excited to be a part of forming the first generic market for Vimovo ®  Tablets and to provide an affordable treatment alternative for patients.” The Vimovo ® (Naproxen and Esomeprazole Magnesium) Delayed-Release Tablets brand had U.S. sales of approximately $414 million MAT for the most recent twelve months ending in December 2019 according to IQVIA Health*.Dr. Reddy’s Naproxen and Esome
Read more